

# Cohort

FY17 results

Marching on

Cohort's earnings performance in FY17 once again exceeded our expectations. Stronger performances from EID and MCL more than outweighed the sharp contraction at SCS, where a swift response from management has already improved profitability. The cash performance was also better than expected and the dividend increase to 7.1p was also ahead of our forecast. We expect further solid progress in the current year, and our fair value estimate currently stands at 471p.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
04/16	112.6	12.0	25.0	6.0	17.2	1.4
04/17	112.7	14.5	26.6	7.1	16.2	1.7
04/18e	123.8	15.4	29.1	8.2	14.8	1.9
04/19e	128.2	16.1	31.3	9.0	13.7	2.1

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and tax credits of 2.20p in FY16 and 1.30p in FY17.

## Progress in a year of change

The strength of performance at MCL and the initial 10-month contribution from EID more than offset a sharper than we expected decline in activity at SCS, and lower than anticipated contributions from MASS and SEA. Proactive management action to reduce costs by integrating SCS into MASS and SEA in early November ensured that the ongoing activities returned a modest profit for the rest of FY17. Overall, Cohort delivered lower revenues than we expected, but an adjusted operating profit 1.4% ahead of our forecast. Adjusted EPS of 27.9p was 3% higher than FY16 (or 7% excluding the tax credits in each year) and 10.5% better than we forecast, due partly to the buy-in of the MCL minority, which should enhance FY18 EPS. Net cash at the year end was £8.5m (FY16: £19.8m) after spending £9.1m on EID and MCL net of cash acquired. The dividend rose 18% to 7.1p (FY16: 6.0p), 3.9x covered.

## Balance sheet remains strong

Cohort is expected to make further progress in FY18, as the company enjoyed healthy order intake during FY17, with a closing order book up 18% at £136.5m (FY16: £116.0m). MCL has notably continued to pick up new work in the current year. The continued conflict between increasing security and defence requirements and budgetary realities continues, but Cohort remains agile in this environment. The balance sheet also continues to enable pursuit of further investment opportunities. The purchase of a further 23% of EID for €4.4m is expected to close soon, which should also enhance earnings.

## Valuation: Performing well against peers

Cohort has experienced a sharp re-rating over the last year. With the prospect of organic growth in FY18 combined with healthy margins, improved free cash flow and strong dividend progression, it continues to perform favourably compared to UK defence peers who have also rerated positively as the outlook for global defence spending improved. Our fair value calculation of 471p (from 485p previously) reflects the sector uplift combined with our reduced earnings estimates.

Aerospace &amp; defence

5 July 2017

**Price** **430.00p**
**Market cap** **£176m**

Net cash (£m) at 30 April 2017 8.5

Shares in issue 40.4m

Free float 70%

Code CHRT

Primary exchange AIM

Secondary exchange N/A

### Share price performance



%	1m	3m	12m
Abs	0.1	(4.6)	42.9
Rel (local)	2.8	(5.3)	25.1

52-week high/low 462.5p 301.0p

### Business description

Cohort is an AIM-listed defence and security company operating across four divisions: MASS (30% of FY18e sales); SEA (40%); MCL (15%); and the 57%-owned Portuguese business EID (15%) acquired in FY17.

### Next events

AGM August 2017

### Analysts

Andy Chambers +44 (0)20 3681 2525

Roger Johnston +44 (0)20 3077 5722

[industrials@edisongroup.com](mailto:industrials@edisongroup.com)
[Edison profile page](#)

**Cohort is a research client of  
Edison Investment Research  
Limited**

## Current trading and outlook

---

### FY17 a mixed year, but solid overall progress

FY17 turned out to be a year of more mixed fortunes for Cohort's divisions than we had expected. While MASS was lower as expected, MCL profits progressed much as anticipated, and EID made a higher initial 10-month operating contribution, with a much higher margin than had been expected. However, SCS saw business levels contract dramatically, with revenues almost halving from the previous year accompanied by a sharp reduction in order intake. In the period up to its reorganisation it delivered a loss of £0.5m, which was more than offset by savings following the transfers into MASS and SEA of its ongoing activities. SEA also traded slightly below expectations as dismantled soldier research project renewals and follow-ons continued to be deferred.

Divisional key points were as follows:

**MASS:** excluding the SCS contribution in the second half, MASS experienced a downturn in sales of 7% and operating profits of 10%. A decline had been anticipated but profits were also affected by a one-off cost of £0.3m and continuing investment in the cyber activities. The closing order book of £41.2m (FY16: £41.7m) was broadly unchanged, excluding an SCS contribution of £8.2m. Order intake was much stronger at £32.0m compared to £20.3m.

**SEA:** on a like-for-like basis, excluding SCS, SEA saw revenues drop to £42.9m (FY16: £48.8m) due to a drop of £6m in R&D contract work for the dismantled soldier programme for the MOD, as well as a tougher trading environment for subsea engineering where revenues dropped to £2m (FY16: £3m). These were partially offset by improved sales to the transport segment and of torpedo launcher systems to overseas customers. The profit performance was also affected by project losses on a one-off towed-array sonar development contract inherited with J+S, which are not expected to recur as the project concludes in the current year. The closing order book of £44.0m included £1.5m from the former SCS businesses and was down from £55.6m in the previous year, largely reflecting the reduction in research contract awards.

**MCL:** delivered strong profit growth of 50% to £2.1m on revenues that were 8% higher at £14.8m. The closing order book of £15.5m compared to just £7.0m at FY16 close, and points to further strong progress this year, although the strong margin performance may ease.

**EID:** the initial strong profit contribution of £4.2m was generated on revenues of £16.0m, a margin of 26.4%. The exceptionally high net margin was due to high levels of support work and export activity, which is expected to normalise in FY18. The closing order book stood at £27.6m following order intake of £18.9m in the 10 months it traded as part of Cohort.

**SCS:** experienced a sharp and persistent reduction in activity in the first half that led management to integrate its ongoing activities between MASS and SEA from November. For the full year, order backlog declined from £11.7m to £9.7m, with intake of just £4.0m. Sales fell to £9.1m from £18.1m in FY16, £5m of which was pre the integration, generating a loss of £0.5m before integration and a profit of £0.8m subsequently. Cost savings of £2.6m should be realised, although an onerous lease accounts for £1m of those and will take time to expire.

Overall the ongoing business saw operating profits decline by 13% on revenues that were 14% lower due to the reductions at SEA and SCS. This was offset by EID's contribution.

The closing order book for FY17 of £136.5m (FY16: £116.0m) included a first contribution from EID of £28.9m. Over £70m of it is due to trade in the current financial year, ahead of the £65m at the same point a year ago. The improvements are despite the sharp reduction at SCS and the

contraction of research orders at SEA. MCL has continued to win significant new hearing protection contracts since the start of the current financial year.

<b>Exhibit 1: Cohort estimates revisions</b>						
Year to April (£m)	2017			2018e		
	Prior	Actual	% change	Prior	New	% change
MASS	30.7	32.5	5.8%	34.1	37.1	8.8%
SCS	17.5	5.0	-71.4%	17.5	0.0	-100.0%
SEA	47.5	44.4	-6.5%	52.0	49.4	-5.0%
MCL	17.0	14.8	-13.2%	18.0	18.5	2.5%
EID	13.1	16.0	22.5%	17.3	18.9	9.5%
<b>Total group revenues</b>	<b>125.8</b>	<b>112.7</b>	<b>-10.4%</b>	<b>138.9</b>	<b>123.8</b>	<b>-10.8%</b>
<b>EBITDA</b>	<b>15.5</b>	<b>15.7</b>	<b>1.5%</b>	<b>17.8</b>	<b>16.7</b>	<b>-6.5%</b>
MASS	6.1	5.9	-3.3%	6.3	6.7	5.9%
SCS	0.2	-0.5	-326.1%	1.2	0.0	-100.0%
SEA	5.4	5.3	-1.8%	5.9	5.9	0.0%
MCL	2.2	2.1	-6.7%	2.3	2.3	-1.4%
EID	2.9	4.2	47.1%	3.5	3.2	-6.9%
HQ Other and intersegment	-2.5	-2.5	0.8%	-2.7	-2.7	0.7%
<b>EBIT (pre-PPA amortisation)</b>	<b>14.3</b>	<b>14.5</b>	<b>1.6%</b>	<b>16.5</b>	<b>15.4</b>	<b>-7.0%</b>
<b>Underlying PTP</b>	<b>14.3</b>	<b>14.5</b>	<b>1.4%</b>	<b>16.6</b>	<b>15.4</b>	<b>-7.1%</b>
<b>EPS - underlying continuing (p)</b>	<b>24.1</b>	<b>26.6</b>	<b>10.5%</b>	<b>33.4</b>	<b>29.1</b>	<b>-12.9%</b>
DPS (p)	7.0	7.1	1.4%	8.0	8.2	2.5%
Net cash/(debt)	7.0	8.5	21.0%	15.7	11.5	-26.6%

Source: Company reports, Edison Investment Research estimates

## Current year expected to show good progress

FY18 will benefit from a full year contribution from EID, albeit margins will revert to more normal levels. In addition, MCL should see healthy revenue and profit gains and the full year benefit of the corrective actions following the SCS restructuring should also boost profitability.

Our FY18 sales forecast is significantly reduced by 11% due to the lower base level of SCS when combined into SEA, although the MASS expectation is broadly maintained. We have increased our revenue expectations for both EID and MCL modestly. Overall our earnings forecasts have been revised downwards by 7%, largely reflecting the reduced contribution from SCS as well as lower margins at EID than we had previously forecast.

We also expect to see steady progression thereafter in line with the improving outlook for defence markets, with the balance sheet expected to benefit from improving cash inflows, which should facilitate the pursuit of further investments.

## Valuation

Rolling both our DCF and peer group valuations forward to a new year results in a fair value estimate of 471p (the average of the two metrics) compared to 485p previously, a 3% reduction. While Cohort has performed strongly over the last 12 months, so has the defence sector generally. However, our FY18e EPS estimate has been reduced by c 13% which brings us in line with market consensus but offsets the upside from the improved defence sector outlook. The headroom from the current share price represents an opportunity as Cohort continues to execute its growth strategy.

**Exhibit 2: Financial summary**

	£m	2015	2016	2017	2018e	2019e
Year end 30 April		IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>						
Revenue		99.9	112.6	112.7	123.8	128.2
Cost of Sales		(70.0)	(79.1)	(73.7)	(87.0)	(90.0)
Gross Profit		30.0	33.5	39.0	36.9	38.2
EBITDA		11.0	13.0	15.7	16.7	17.4
Operating Profit (before amort. and except.)		10.1	11.9	14.5	15.4	16.0
Intangible Amortisation		(3.6)	(6.4)	(11.3)	(5.2)	(3.9)
Exceptionals		(0.6)	(0.3)	(2.3)	0.0	0.0
Other		0.0	0.0	0.0	0.0	0.0
Operating Profit		5.9	5.2	1.0	10.2	12.1
Net Interest		0.1	0.1	0.0	0.0	0.0
Profit Before Tax (norm)		10.2	12.0	14.5	15.4	16.1
Profit Before Tax (FRS 3)		5.9	5.3	1.0	10.2	12.1
Tax		(0.7)	0.1	1.1	(1.9)	(2.2)
Profit After Tax (norm)		8.9	11.2	11.4	12.7	13.2
Profit After Tax (FRS 3)		5.2	5.4	2.1	8.3	10.0
Average Number of Shares Outstanding (m)		40.1	40.6	40.4	40.4	40.4
EPS - normalised (p)*		20.5	27.2	27.9	29.1	31.3
EPS - normalised and fully diluted (p)		20.0	26.7	27.6	28.7	30.9
EPS - (IFRS) (p)		11.2	12.7	9.1	18.3	23.2
Dividend per share (p)		5.0	6.0	7.1	8.2	9.0
Gross Margin (%)		30.0	29.8	34.6	29.8	29.8
EBITDA Margin (%)		11.0	11.5	13.9	13.5	13.5
Operating Margin (before GW and except.) (%)		10.1	10.6	12.9	12.4	12.5
<b>BALANCE SHEET</b>						
Fixed Assets		66.2	59.7	60.6	55.1	50.9
Intangible Assets		55.8	49.5	50.6	45.4	41.5
Tangible Assets		10.3	10.2	9.9	9.7	9.4
Investments		0.0	0.0	0.0	0.0	0.0
Current Assets		40.3	54.0	56.3	70.6	81.5
Stocks		1.1	2.0	5.3	6.0	6.4
Debtors		19.4	27.3	37.3	41.0	42.4
Cash		19.7	23.1	12.0	22.0	31.0
Other		0.1	1.6	1.7	1.7	1.7
Current Liabilities		(26.8)	(40.1)	(39.7)	(33.1)	(29.9)
Creditors		(26.8)	(36.8)	(36.1)	(33.1)	(29.9)
Short term borrowings		(0.0)	(3.3)	(3.5)	0.0	0.0
Long Term Liabilities		(16.9)	(2.7)	(3.2)	(13.7)	(17.2)
Long term borrowings		(0.0)	(0.0)	(0.0)	(10.5)	(14.0)
Other long term liabilities		(16.8)	(2.7)	(3.2)	(3.2)	(3.2)
Net Assets		62.8	70.8	74.0	79.0	85.3
<b>CASH FLOW</b>						
Operating Cash Flow		20.5	8.5	3.8	9.8	12.7
Net Interest		0.1	0.1	0.0	0.0	0.0
Tax		(1.7)	(1.8)	(3.1)	(2.7)	(2.8)
Capex		(1.1)	(1.0)	(0.9)	(1.1)	(1.1)
Acquisitions/disposals		(13.5)	(0.7)	(9.1)	0.0	0.0
Financing		0.8	(3.2)	0.5	0.0	0.0
Dividends		(1.8)	(2.2)	(2.5)	(3.0)	(3.4)
Net Cash Flow		3.3	(0.3)	(11.4)	3.1	5.5
Opening net debt/(cash)		(16.3)	(19.7)	(19.8)	(8.5)	(11.5)
HP finance leases initiated		0.0	0.0	0.0	0.0	0.0
Other		(0.0)	0.5	0.0	(0.0)	0.0
Closing net debt/(cash)		(19.7)	(19.8)	(8.5)	(11.5)	(17.0)

Source: Company accounts, Edison Investment Research, Note: \*Includes non-recurring tax credits in FY16 and FY17.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cohort and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.